ATE489968T1 - Proteosom-liposaccharid-vakzine-adjuvans - Google Patents

Proteosom-liposaccharid-vakzine-adjuvans

Info

Publication number
ATE489968T1
ATE489968T1 AT02713807T AT02713807T ATE489968T1 AT E489968 T1 ATE489968 T1 AT E489968T1 AT 02713807 T AT02713807 T AT 02713807T AT 02713807 T AT02713807 T AT 02713807T AT E489968 T1 ATE489968 T1 AT E489968T1
Authority
AT
Austria
Prior art keywords
liposaccharide
proteosome
variety
vaccine adjuvant
bacterial
Prior art date
Application number
AT02713807T
Other languages
English (en)
Inventor
David Burt
George Lowell
Gregory White
David Jones
Clement Rioux
Original Assignee
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec
Application granted granted Critical
Publication of ATE489968T1 publication Critical patent/ATE489968T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT02713807T 2001-03-09 2002-03-11 Proteosom-liposaccharid-vakzine-adjuvans ATE489968T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27423201P 2001-03-09 2001-03-09
US32729701P 2001-10-09 2001-10-09
PCT/US2002/007108 WO2002072012A2 (en) 2001-03-09 2002-03-11 A novel proteosome-liposaccharide vaccine adjuvant

Publications (1)

Publication Number Publication Date
ATE489968T1 true ATE489968T1 (de) 2010-12-15

Family

ID=26956684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713807T ATE489968T1 (de) 2001-03-09 2002-03-11 Proteosom-liposaccharid-vakzine-adjuvans

Country Status (9)

Country Link
US (2) US7524509B2 (de)
EP (1) EP1372706B1 (de)
JP (2) JP4137640B2 (de)
AT (1) ATE489968T1 (de)
AU (1) AU2002245636B2 (de)
CA (1) CA2438425C (de)
DE (1) DE60238471D1 (de)
MX (1) MXPA03008154A (de)
WO (1) WO2002072012A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
CA2524485A1 (en) * 2003-05-05 2004-11-18 Id Biomedical Corporation Of Quebec Vaccinating against infectious diseases using proteosomes
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US20050152919A1 (en) * 2003-09-15 2005-07-14 Id Biomedical Corporation Of Quebec Measles subunit vaccine
WO2005042017A1 (en) 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CU23420A1 (es) * 2003-12-30 2009-09-08 Univ De Cambridge Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes
CN101039691B (zh) * 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
EP1778283A2 (de) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccinzusammensetzungen zur behandlung von coronavirusinfektion
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
EP4585610A3 (de) 2006-09-11 2025-09-24 Seqirus UK Limited Herstellung von influenzavirus-impfstoffen ohne verwendung von eiern
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
US20110189231A1 (en) * 2008-06-17 2011-08-04 Denis Leclerc Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
JP4363579B1 (ja) 2008-06-18 2009-11-11 曜顯 松下 表示板と表示板支持部材から成る表示板装填物
WO2010028246A2 (en) 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
US20100275282A1 (en) * 2009-04-23 2010-10-28 Round June L Methods and systems for identifying immunomodulatory substances
HUE028085T2 (en) 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
EP2445527A2 (de) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Impfstoff
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
WO2011106525A2 (en) 2010-02-26 2011-09-01 The Brigham And Women's Hospital, Inc. Methods of treating cerebral amyloid angiopathy
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012055951A2 (en) 2010-10-27 2012-05-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EP2970398B1 (de) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Rsv-f-prefusionsproteine und deren verwendung
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
CA2911826C (en) 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
AU2015384786B2 (en) 2015-03-03 2020-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN118510790A (zh) 2021-12-13 2024-08-16 美国政府(由卫生和人类服务部的部长所代表) 噬菌体λ-疫苗系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0688205A1 (de) * 1993-03-11 1995-12-27 Secretech, Inc. Mucoadhäsive polymere in der verabreichung von immunogenen an muköse oberflächen
ATE223702T1 (de) * 1993-10-22 2002-09-15 Genentech Inc Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
AU739723B2 (en) 1996-07-10 2001-10-18 Government Of The United States Of America, As Represented By The Secretary Of The Army, The Protein and peptide vaccines for inducing mucosal immunity
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
CA2400468C (en) * 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US20050152919A1 (en) * 2003-09-15 2005-07-14 Id Biomedical Corporation Of Quebec Measles subunit vaccine
WO2005042017A1 (en) * 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
EP1778283A2 (de) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccinzusammensetzungen zur behandlung von coronavirusinfektion
US20060228233A1 (en) * 2005-03-31 2006-10-12 Arimitsu Of North America, Inc. Pump and motor assembly

Also Published As

Publication number Publication date
MXPA03008154A (es) 2004-11-12
US20030044425A1 (en) 2003-03-06
JP2004521925A (ja) 2004-07-22
WO2002072012A2 (en) 2002-09-19
CA2438425C (en) 2012-05-01
EP1372706A4 (de) 2004-08-25
US20090252762A1 (en) 2009-10-08
JP4137640B2 (ja) 2008-08-20
US7524509B2 (en) 2009-04-28
EP1372706A2 (de) 2004-01-02
CA2438425A1 (en) 2002-09-19
JP2007031457A (ja) 2007-02-08
DE60238471D1 (de) 2011-01-13
AU2002245636B2 (en) 2004-10-14
WO2002072012A3 (en) 2003-02-27
EP1372706B1 (de) 2010-12-01

Similar Documents

Publication Publication Date Title
ATE489968T1 (de) Proteosom-liposaccharid-vakzine-adjuvans
DK0764029T4 (da) Proteinadjuvanser
CY1107561T1 (el) Εμβoλιο kata του πνευμονιοκοκκου
DE60226911D1 (de) Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
YU153291A (sh) Poboljšani vakcinski preparati
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
MXPA01007760A (es) Compuesto adyuvante inmunologico.
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
ATE529130T1 (de) Trockenformulierung für transkutane immunisierung
CA2311492A1 (en) Vaccines with an ltb adjuvant
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
EP1395283A4 (de) Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
EA200700496A1 (ru) Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
EP1438066A4 (de) Inaktivierte immunogene bakterielle ganzzell-zusammensetzungen
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
WO2001015727A3 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
WO2002060390A3 (en) Induction of immune responses to isoaspartyl-modified antigens
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
WO2001040472A3 (en) Streptococcus pneumoniae antigens
WO2001043769A3 (en) Antigen delivery

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties